N4-甲基-2,4,6-嘧啶三胺 | 24867-24-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: N4-甲基-2,4,6-嘧啶三胺
• 英文名称: 6-chloro-2,4-diaminopyrimidine
• 英文别名: N⁴-methyl-pyrimidine-2,4,6-triamine；N⁴-methyl-pyrimidine-2,4,6-triyltriamine；N⁴-Methyl-pyrimidin-2,4,6-triyltriamin；2,4-diamino-6-methylaminopyrimidine；2,4-Diamino-6-methylaminopyrimidin；2,4,6-Pyrimidinetriamine, N4-methyl-；4-N-methylpyrimidine-2,4,6-triamine
• CAS: 24867-24-1
• 化学式: C₅H₉N₅
• 分子量: 139.16
• InChiKey: VORFXKKTHAMEJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  89.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N4-甲基-2,4,6-嘧啶三胺 在 potassium hydroxide 、 三氯氧磷 作用下， 以 乙醇 为溶剂， 生成 7-(2,3-dichlorophenyl)-4-N-methylpyrido[2,3-d]pyrimidine-2,4-diamine
  参考文献：
  名称：

  7-Phenyl-pyrido[2,3-d]pyrimidine-2,4-diamines: Novel and highly selective protein tyrosine phosphatase 1B inhibitors

  摘要：

  High throughput screening of the Roche compound collection led to the identification of diaminopyrroloquinazoline series as a novel class of PTP1B inhibitors. Structural modification of diaminopyrroloquinazoline series resulted in pyrido[2,3-d]pyrimidine-2,4-diamine series which was further optimized to give compounds 5 and 24 as potent, selective (except T-cell phosphatase) PTP1B inhibitors with good mouse PK properties. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.10.035
• 作为产物：
  描述：

  2,4-二氨基-6-氯嘧啶 、 甲胺 以 水 为溶剂， 反应 4.5h， 以33%的产率得到N4-甲基-2,4,6-嘧啶三胺
  参考文献：
  名称：

  Pyridopyrimidine protein tyrosine phosphatase inhibitors

  摘要：

  本发明包括一般式I的吡啶吡嘧啶二胺化合物： 本发明的化合物是PTP1B的有效抑制剂。因此，该发明还涵盖了制药组合物和治疗或预防PTP-1B介导的疾病，包括糖尿病、肥胖和与糖尿病相关的疾病的方法。

  公开号：

  US20070021445A1

文献信息

• Pyridopyrimidine protein tyrosine phosphatase inhibitors
  申请人：Berthel Joseph Steven

  公开号：US20070021445A1

  公开（公告）日：2007-01-25

  The present invention comprises pyridopyrimidinediamine compounds of the general formula I: The compounds of the present invention are potent inhibitors of PTP1B. Accordingly, the invention also encompasses pharmaceutical compositions and methods of treating or preventing PTP-1B mediated diseases, including diabetes, obesity, and diabetes-related diseases.

  本发明包括一般式I的吡啶吡嘧啶二胺化合物： 本发明的化合物是PTP1B的有效抑制剂。因此，该发明还涵盖了制药组合物和治疗或预防PTP-1B介导的疾病，包括糖尿病、肥胖和与糖尿病相关的疾病的方法。
• Studies on Condensed Pyrimidine Systems. XI. Some 8-Alkyl-7-pteridones¹
  作者：Gertrude B. Elion、George H. Hitchings

  DOI：10.1021/ja01113a050

  日期：1953.9
• Analogs of Pteroylglutamic Acid. V. 4-Alkylamino Derivatives
  作者：Barbara Roth、James M. Smith、Martin E. Hultquist

  DOI：10.1021/ja01161a017

  日期：1950.5
• 7-Phenyl-pyrido[2,3-d]pyrimidine-2,4-diamines: Novel and highly selective protein tyrosine phosphatase 1B inhibitors
  作者：Adrian Wai-Hing Cheung、Bruce Banner、Jolly Bose、Kyungjin Kim、Shiming Li、Nicholas Marcopulos、Lucja Orzechowski、Joseph A. Sergi、Kshitij C. Thakkar、Bing-Bing Wang、Weiya Yun、Catherine Zwingelstein、Steven Berthel、Andrée R. Olivier

  DOI：10.1016/j.bmcl.2012.10.035

  日期：2012.12

  High throughput screening of the Roche compound collection led to the identification of diaminopyrroloquinazoline series as a novel class of PTP1B inhibitors. Structural modification of diaminopyrroloquinazoline series resulted in pyrido[2,3-d]pyrimidine-2,4-diamine series which was further optimized to give compounds 5 and 24 as potent, selective (except T-cell phosphatase) PTP1B inhibitors with good mouse PK properties. (C) 2012 Elsevier Ltd. All rights reserved.